AQST Stock Analysis: Buy, Sell, or Hold?
AQST - Aquestive Therapeutics, Inc. Common Stock
$4.04
0.02 (0.37%)
▲
5d:
+2.67%
30d:
+0.88%
90d:
-32.64%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 11, 2026
Smart Money Accumulation
AQST is down 6.6% this week, but smart money is accumulating calls. Top strike: $5 2026-05-15 with 4,192 OI. Call ratio: 87% View Scanner →
Strength: 7.0/10
Get Alerted When AQST Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: AQST shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: AQST shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: AQST is currently trading at $4.04, which is considered slightly low relative to its 30-day fair value range of $3.98 to $4.22.
Technical Outlook: Technically, AQST is in a strong uptrend. Immediate support is located at $3.77, while resistance sits at $4.30.
Market Sentiment: AQST has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.89 (+121.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AQST is in a strong uptrend. Immediate support is located at $3.77, while resistance sits at $4.30.
Market Sentiment: AQST has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.89 (+121.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$3.98 -
$4.22
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 121.1% below Wall St target ($8.89)
Fair Price Analysis
30-Day Fair Range
$3.98 -
$4.22
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.77
Resistance Level
$4.30
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.93
Wall Street Target
$8.89
(+121.1%)
Revenue Growth (YoY)
9.7%
Profit Margin
-188.1%
Share & Embed Analysis
Last updated: March 30, 2026 1:42 PM ET
Data refreshes hourly during market hours. Next update: 2:42 PM
Data refreshes hourly during market hours. Next update: 2:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AQST showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
A Ernest Toth Jr
SELL
58254 shares
2026-03-10
Cassie Jung
SELL
45791 shares
2026-03-10
Daniel Barber
SELL
180677 shares
2026-03-10
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 60 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 58 HOLD |
